Cochlear (ASX: COH) significantly cut its full-year underlying net profit after tax guidance by 23% at the midpoint to AUD 290 million-AUD 330 million from the implied guidance in February 2026 of AUD 405 million. The downgrade was mostly due to higher costs expected and soft market growth. Shares fell 41%.

Why it matters: The market was blindsided when full-year guidance came in well below the FactSet consensus, and the headwinds appeared more structural. We cut our revenue and underlying NPAT forecasts by 14% and 35% on average over the next 10 years, respectively.

  • We reduce our forecast 10-year cochlear implant sales growth to 5%, from 6% previously. Cochlear implants are becoming more discretionary for adults and seniors due to cost-of-living pressures in the US and hospital capacity constraints in Europe. War in the Middle East is also affecting emerging-market sales.
  • Due to a lower sales forecast, we expect lower overhead absorption and higher investment required in the challenged adult and seniors segment. We cut our midcycle NPAT margin to 14% from 19% prior, versus an estimated 15% in fiscal 2026 and the firm’s long-term target of 18%.

The bottom line: We cut our fair value estimate for wide-moat Cochlear by 51% to AUD 110. With the firm reducing its manufacturing output due to lower consumer demand, we now expect lower earnings growth for longer, driven by lower forecast sales and broadly flat margins. Shares trade at a slight discount.

  • From fiscal 2027, we forecast revenue growth of 7% on average versus guidance of roughly 4% in the second half, driven by increasing uptake of the new Nexa product and emerging markets with faster birth rates and rising affordability.
  • However, we cut our long-term gross margin assumption to 72% from 75% prior. We now expect margins to be broadly flat with overhead absorption improving as volumes recover from current lows, but offset by a greater mix shift to lower-price emerging markets.

Cochlear Facing Long-Term Headwinds With Adults and Seniors Deprioritising Implants

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

We estimate roughly 65% of units are sold to developed markets and the remaining 35% to emerging markets, where over 90% are for children. Large price differentials in the lower range of products result in 80% of revenue being earned in developed markets and 20% in tender-oriented emerging markets. We estimate average unit prices achieved in developed markets are roughly double those in emerging markets.

In the developed-markets children segment, the growth tailwinds from increasing market penetration and the shift from single to bilateral implants over the last 15 years have played out, and we forecast growth in this segment to reduce to the birthrate over time.

The adult developed market is more difficult to penetrate, and we expect required investment to expand this segment will restrain significant operating margin expansion. Currently, penetration is still estimated to be under 5%, and Cochlear is at a pivot point as it invests to be adopted more widely by seniors with profound hearing loss. Prevalence of profound hearing loss increases over 65 years and has a steep increase over 80 years of age. As such, an ageing population and low penetration suggest a large opportunity.

However, hearing aids, not cochlear implants, are the standard of care. Cochlear is investing significantly to increase awareness as well as funding research to support payer reimbursement. But we see two main challenges to accessing this market fully: first, the relatively low willingness of older candidates to undertake such invasive surgery, and second, the improvements in hearing aids. The hearing aid market is increasing its penetration in the severe hearing loss category, leaving only the smaller profound hearing loss as the cochlear implant niche.

Bulls Say

  • There are signs Cochlear is looking to expand beyond the hearing market with the investment in Nyxoah, a company focused on hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea.
  • The annuitylike revenue stream from sound processor upgrades and accessories is an increasingly important component of the revenue stream.
  • Cochlear earns ROICs well ahead of the cost of capital, which is testament to the high quality of the company.

Bears Say

  • Growth in the cochlear implant market is becoming more costly to achieve, limiting the potential upside to earnings.
  • The arrival of low-cost competitor Nurotron could disrupt markets other than China, and this could trigger price deflation.
  • Growth in emerging markets such as China, India, and Latin America weighs on margins due to lower average prices.

Get Morningstar insights in your inbox

Terms used in this article

Fair Value: Morningstar’s Fair Value estimate results from a detailed projection of a company’s future cash flows, resulting from our analysts’ independent primary research. Price To Fair Value measures the current market price against estimated Fair Value. If a company’s stock trades at $100 and our analysts believe it is worth $200, the price to fair value ratio would be 0.5. A Price to Fair Value over 1 suggests the share is overvalued.

Moat Rating: An economic moat is a structural feature that allows a firm to sustain excess profits over a long period. Companies with a narrow moat are those we believe are more likely than not to sustain excess returns for at least a decade. For wide-moat companies, we have high confidence that excess returns will persist for 10 years and are likely to persist at least 20 years. To learn about finding different sources of moat, read this article by Mark LaMonica.